Cat. No. 1793
Biological ActivityPotent and selective antagonist for the human type I interleukin-1 (IL-1) receptor (IC50 values are 8 nM, > 6.7 mM and > 200 mM for human type I, human type II and murine type I IL-1 receptors respectively). Blocks IL-1-induced expression of ICAM-1 and E-selectin in HUVECs and IL-1β induction of IL-8 in human dermal fibroblasts. Reduces IL-1β-induced IL-6 production and exhibits anti-inflammatory activity in vivo.
(Modifications: Phe-1 = N-terminal Ac, X - Aze, Leu-15 = C-terminal amide)
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Aimbire et al (2008) Low level laser therapy (LLLT) decreases pulmonary microvascular leakage, neutrophil influx and IL-1β levels in airway and lung from rat subjected to LPS-induced inflammation. Inflammation 31 189. PMID: 18421573.
Akeson et al (1996) AF12198, a novel low molecular weight antagonist, selectively binds the human type I interleukin (IL)-1 receptor and blocks in vivo responses to IL-1. J.Biol.Chem. 271 30517. PMID: 8940020.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products. Selected citations for AF 12198 include:
Lin et al (2010) Interleukin-1β expression is required for lysophosphatidic Acid-induced lymphangiogenesis in human umbilical vein endothelial cells. J Psychopharmacol 2011 351010. PMID: 21151531.
Do you know of a great paper that uses AF 12198 from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: AF 12198, supplier, Potent, selective, human, type, I, IL-1, receptors, antagonists, IL, Interleukins, Cytokines, AF12198, Tocris Bioscience, Cytokine Receptor Antagonist products
Find multiple products by catalog number
New Products in this Area
Potent and selective inhibitor of integrins αvβ3 and αvβ5SM 324405
Potent TLR7 agonistRS 09
TLR4 peptide agonist; acts as an adjuvant in vivo
October 30 - November 3, 2016
Boston, MA, USA